Vetter Dedicates New Facility in Suburban Chicago

04-Dec-2009 - USA

Developing drugs is a slow and expensive process, especially for hard-to-treat diseases such as cancer. Biopharmaceutical companies are continuously seeking ways to accelerate development and control costs. With the dedication of its new 24,000-square-foot facility at the Illinois Science + Technology Park in Skokie, Vetter may enable life-sciences firms to streamline their early development process and cut time to market.

“For injectable drugs, collaboration early in development is essential,” said Peter Soelkner, Vetter`s managing director. “What is the most user-friendly injection system for the patient? Should the compound be liquid or freeze-dried and reconstituted? What delivery system would best ensure multinational regulatory approval? Getting the answers right — the first time — speeds medications to market and to the patients that need them.”

The Skokie site at 8025 Lamon Avenue, Vetter’s first U.S. facility and its first outside Germany, will eventually employ 50 to 60 highly skilled professionals.

“Since nearly half of our customer base is located in North America, creating a U.S. facility was the logical next step,” said Soelkner. “Although we did consider several other U.S. biotech hotspots, including Boston and San Francisco, Chicago best suited our needs.”

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances